Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Beijing Konruns Pharmaceutical Co Ltd
603590Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China. Address: No. 11, Xingsheng South Road, Beijing, China
Analytics
Precio Objetivo de WallStreet
322.02 CNYRelación P/E
34.4658Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 603590
Análisis de dividendos 603590
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
36 %Tendencia del payout 603590
Valoración de la acción 603590
Finanzas 603590
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |